Tocagen plummets on phase 3 data for glioma therapyA phase 3 trial of Tocagen’s therapy for high-grade glioma (HGG) – a form of brain cancer – Share XTocagen plummets on phase 3 data for glioma therapyhttps://pharmaphorum.com/news/tocagen-plummets-on-phase-3-data-for-glioma-therapy/
Tocagen’s brain tumour candidate gets PRIME designationAn early-stage drug candidate for hard-to-treat brain tumours has been granted special ‘PRIME’ status by the European Medicines Share XTocagen’s brain tumour candidate gets PRIME designationhttps://pharmaphorum.com/news/tocagens-brain-tumour-treatment-gets-prime-designation/
Tocagen aims for IPO to fund brain cancer trialBrain cancer specialist Tocagen is to become the latest biotech to test the waters with an IPO this Share XTocagen aims for IPO to fund brain cancer trialhttps://pharmaphorum.com/news/tocagen-aims-ipo-fund-brain-cancer-trial/
